"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of selexipag (Uptravi, Actelion Registration Ltd) for the treatment of adults with pulmonary arterial hypertension (PAH)./"...
Calan SR Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Calan SR (verapamil hydrochloride) is a calcium ion antagonist used to treat hypertension (high blood pressure). Calan SR is available in generic form. Common side effects of Calan SR include constipation, dizziness, lightheadedness, nausea, low blood pressure (hypotension), headache, swelling, fatigue, shortness of breath, irregular heart rate, rash, and flushing.
The initial dose of Calan SR is 180 mg, given in the morning. Calan SR may interact with simvastatin, atorvastatin, beta-blockers, digitalis, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, diuretics, disopyramide, flecainide, quinidine, alcohol, lithium, carbamazepine, rifampin, phenobarbital, cyclosporine, theophylline, inhalation anesthetics, neuromuscular blocking agents, telithromycin, and clonidine. Tell your doctor all medications and supplements you use. During pregnancy, Calan SR should be used only if prescribed. Calan SR passes into breast milk. Breastfeeding is not recommended while using Calan SR.
Our Calan SR (verapamil hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Calan SR FDA Prescribing Information: Side Effects
Serious adverse reactions are uncommon when verapamil therapy is initiated with upward dose titration within the recommended single and total daily dose. See WARNINGS for discussion of heart failure, hypotension, elevated liver enzymes, AV block, and rapid ventricular response. Reversible (upon discontinuation of verapamil) non-obstructive, paralytic ileus has been infrequently reported in association with the use of verapamil. The following reactions to orally administered verapamil occurred at rates greater than 1.0% or occurred at lower rates but appeared clearly drug-related in clinical trials in 4,954 patients:
|CHF, Pulmonary edema||1.8%|
|Bradycardia (HR < 50/min)||1.4%|
|AV block (total 1°, 2°, 3°)||1.2%|
|(2° and 3°)||0.8%|
|Elevated liver enzymes (see WARNINGS)|
In clinical trials related to the control of ventricular response in digitalized patients who had atrial fibrillation or flutter, ventricular rates below 50/min at rest occurred in 15% of patients and asymptomatic hypotension occurred in 5% of patients.
The following reactions, reported in 1% or less of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:
Hemic and lymphatic: ecchymosis or bruising.
Special senses: blurred vision, tinnitus.
Treatment Of Acute Cardiovascular Adverse Reactions
The frequency of cardiovascular adverse reactions that require therapy is rare; hence, experience with their treatment is limited. Whenever severe hypotension or complete AV block occurs following oral administration of verapamil, the appropriate emergency measures should be applied immediately; eg, intravenously administered norepinephrine bitartrate, atropine sulfate, isoproterenol HCl (all in the usual doses), or calcium gluconate (10% solution). In patients with hypertrophic cardiomyopathy (IHSS), alpha-adrenergic agents (phenylephrine HCl, metaraminol bitartrate, or methoxamine HCl) should be used to maintain blood pressure, and isoproterenol and norepinephrine should be avoided. If further support is necessary, dopamine HCl or dobutamine HCl may be administered. Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.
Read the entire FDA prescribing information for Calan SR (Verapamil Hydrochloride Sustained-Release Oral Caplets)
Additional Calan SR Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.